A differentiated therapeutic approach to overactive bladder in elderly and senile women


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper considers the main problems of diagnosis and rational therapy of overactive bladder (OAB) in elderly and senile women. It is known that age-related changes in the body can lead to pronounced changes in the pharmacokinetics of drugs, since the number, density, and sensitivity of receptors can be changed, which contributes to the strengthening or weakening of the main pharmacological effect. For many decades, anticholinergic drugs have been positioned among the first-line treatments. OAB is a syndrome that requires longterm, often lifelong treatment. At the same time, the long-term use of M-anticholinergics is frequently accompanied by an inadequate response and pronounced side effects in the group of elderly patients, which substantially limits their long-term use and had often led to discontinuation of the drug by the patient himself. At present, mirabegron, a beta-3-adrenergic receptor agonist that relaxes the detrusor is regarded as the first-line therapy in elderly and senile patients. Numerous randomized studies have proven the efficacy and good tolerability of the drug and the absence of its effect on cognitive functions. Conclusion. Taking into account the age-related characteristics of homeostasis and metabolism in elderly women, Mirabegron 50 mg can be recommended as the drug of choice when blood pressure and pulse rate are controlled. In addition, local estrogen therapy is indicated for postmenopausal women with urgent urinary incontinence. Mirabegron is a selective beta-3-adrenergic agonist; therefore it does not cause side effects, such as dry mouth, elevated intraocular pressure, constipation, and impaired cognitive functions, or affect the parasympathetic stimulation of detrusor contraction and bladder emptying, and therefore, this drug, unlike antimuscarinic agents, may reduce the risk of acute urinary retention. In this connection, mirabegron is also recommended for the treatment of de novo urgency and OAB in women after sling urethropexy.

全文:

受限制的访问

作者简介

Inna Apolikhina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: apolikhina@inbox.ru
MD, Head of the Department of Aesthetic Gynecology and Rehabilitation

Tatyana Teterina

Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: t_teterina@oparina4.ru
PhD, obstetrician-gynecologist of the Department of Aesthetic Gynecology and Rehabilitation

Ekaterina Atamanova

JSC «Astellas Pharma»

Email: ekaterina.atamanova@astellas.com
MD, PhD, Medical Advisor

参考

  1. Abrams P., Cardozo L, Wagg A., Wein A., eds. Incontinence. 6th ed. Bristol: International Continence Society; 2017.
  2. Мазо Е.Б., Школьников М.Е., Кривобородов Г.Г. Гиперактивный мочевой пузырь у больных пожилого возраста. Consilium Medicum. 2006; 8(12): 97-101. [Mazo E.B., Shkolnikov M.E., Krivoborodov G.G. Overactive bladder in elderly patients. Urology. 2006: 6. (in Russian)].
  3. Пушкарь Д.Ю. Синдром гиперактивного мочевого пузыря в клинической практике врача уролога. Методические рекомендации №2. М.; 2016. [Pushkar D.Yu. Overactive bladder syndrome in the clinical practice of urologist. Methodical recommendations №2. Mosev, 2016. (in Russian)].
  4. Thuroff J.W, Abrams P., Schroder A., Andersson K.-E., Artibani, Chappie C.R. et al. Рекомендации европейской ассоциации урологов: недержание мочи. Перевод Алымов Ю.В., Велиев Е.И., ред. Европейская ассоциация урологов; 2010. Available at: http://www. uroweb.org/gls/pdf/russian/11_ Urinary_Inc.pdf
  5. Парфенов В.А. Неврологические аспекты недержания мочи у пожилых людей. Неврология, нейропсихиатрия, психосоматика. 2013; 1: 34-8. [Parfenov V.A Neurological aspects of urinary incontinence in the elderly. Neurology, neuropsychiatry, psychosomatics. 2013; 1: 34-8. (in Russian)].
  6. Тетерина Т.А., Аполихина И.А., Глыбочко П.В., Безнощенко О.С., Кречетова Л.В. Дифференцированный подход к диагностике резистентного гиперактивного мочевого пузыря у женщин. Эффективная фармакотерапия. 2014; 41: 18-23. [Teterina T.A., Apolikhina I.A., Glybochko P.V. et al. Differentiated approach to the diagnosis of resistant overactive bladder in women. Effective pharmacotherapy. 2014; 41: 18-23. (in Russian)].
  7. Ушкалова Е.А., Ткачева О.Н., Рунихина Н.К., Чухарева Н.А., Бевз А.Ю. Особенности фармакотерапии у пожилых пациентов. Введение в про блему. Рациональная фармакотерапия в кардиологии. 2016; 12(1): 94-100. [Ushkalova E.A., Tkacheva O.N., Runikhina N.K., Chukhareva N.A., Bevz A.Yu. Features of pharmacotherapy in elderly patients. Introduction to the problem. Rational Pharmacotherapy in Cardiology 2016; 12 (1): 94-100. (in Russian)].
  8. Резолюция по итогам совещания экспертов по лечению гиперактивного мочевого пузыря. Москва, 30 марта 2018г. Consilium Medicum. 2018; 20(7): 61-2. [Resolution following an expert meeting on OAB treatment. Apolikhina I.A., Bezhenar V.F. and others, 2018. (in Russian)].
  9. Аполихина И.А., Чочуева А.С., Саидова А.С., Горбунова Е.А. Современные возможности медикаментозного лечения гиперактивного мочевого пузыря у женщин. Медицинский совет. 2017; 2: 122-7. [Apolikhina I.A., Chochueva A.S., Saidova A.S., Gorbunov E.A. Modern possibilities of drug treatment of overactive bladder in women. Medical advice. 2017; 2: 122-7. (in Russian)].
  10. European urological association guidelines. 2020. Available at: https://uroweb. org/guideline/urinary-incontinence/
  11. Рекомендации МЗ по Фармакотерапии у лиц пожилого и старческого возраста. 2018: 68-71. [Recommendations of the Ministry of Health for Pharmacotherapy in the elderly and senile. 2018; 68-71. (in Russian)]. Available at: https://vrachirf.ru/storage/58/e2/a0/3c/21/fb/81/ab/4a70-f6450a-b7d703. PDF.
  12. FDA Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron. 2012. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Reproductive HealthDrugs AdvisoryCommittee/UCM298284.pdf
  13. Chappie C., Amarenco G., Lopez Aramburu M., Everaert K., Liehne J., Lucas M. et al. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurouro.l Urodyn. 2013; 32(8): 1116-22. https://dx.doi.org/10.1002/ nau.22373.
  14. Chappie C., Dvorak V., Radziszewski P., Van Kerrebroeck P., Wyndaeie J., Bosman B. et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int. Urogynecol. J. 2013; 24(9): 1447-58. https:// dx.doi.org/10.1007/s00192-013-2042-x.
  15. Nitti V., Herschorn S., Auerbach S., Maggie Ayers M., Misun Lee M., N. Martin N. et al. The selective [beta] 3-adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome. J. Urol. 2011; 185(4): e783-4.
  16. Herschorn S., Chappie C.R., Abrams P., Ariandis S., Mitcheson D., Lee K.S. et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017; 120(4): 562-75. https://dx.doi.org/10.1111/bju.13882.
  17. Rossanese M., Novara G., Chaiiacombe B., Iannetti A., Dasgupta P., Ficarra V. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a beta(3)-adrenoceptor agonist (mirabegron) for overactive bladder (OAB). BJU Int. 2015; 115(1): 32-40. https://dx.doi. org/10.1111/bju.12730.
  18. Rosa G., Ferrero S., Nitti V., Wagg A., Saieem T., Chappie C. Cardiovascular safety of beta3- adrenoceptor agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016; 69(2): 311-23. https://dx.doi.org/10.1016/j. eururo.2015.09.007.
  19. Khuiiar V., Amarenco G., Angulo J.C., Cambronero J., H0ye K., Miisom I. et al. Efficacy and tolerability of mirabegron, a (3(3)- adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013; 63(2): 283-95. https://dx.doi.org/10.1016/j. eururo.2012.10.016.
  20. Chappie C., Kaplan S., Mitcheson H., Kiecka J., Cummings J., Drogendijk T. et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a [3(3)adrenoceptor agonist, in overactive bladder (OAB). Eur. Urol. 2013; 62(2): 296-305. https://dx.doi.org/10.1016/j. eururo.2012.10.048.
  21. Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. Drugs. 2013; 73(11): 1213-25. https://dx.doi.org/10.1007/s40265-013-0086-3.
  22. Kato D, Tabuchi H., Uno S. Three year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study. Low. Urin. Tract Symptoms. 2019; 11(2): 152-61. https://dx.doi.org/ https://doi.org/10.1111/luts.12237.
  23. Wagg A, Staskin D., Engel E., Herschorn S., Kristy R.M., Schemer C.R. et al. Efficacy, safety, and tolerability of mirabegron in patients aged 65 year with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur. Urol. 2020; 77(2): 211-20. https://dx.doi. org/10.1016/j.eururo.2019.10.002.
  24. Ozkidik M., Co§kun A., Asutay M.K., Bahgeci T., Hamidi N. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence. Int. Braz. J. Urol. 2019; 45(4): 782-9. https://dx.doi.org/10.1590/S1677-5538.IBJU. 2018.0518.
  25. Menopause: diagnosis and management. NICE; 2019. Available at: https:// www.nice.org.uk/guidance/ng23/chapter/Recommendationstinformation-and-advice

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2020